1. Home
  2. EPOW vs FEMY Comparison

EPOW vs FEMY Comparison

Compare EPOW & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.96

Market Cap

45.7M

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.86

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
FEMY
Founded
2014
2004
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.7M
51.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EPOW
FEMY
Price
$0.96
$0.86
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.83
AVG Volume (30 Days)
249.6K
1.9M
Earning Date
01-01-0001
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$64,997,741.00
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
N/A
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
44.28
63.53
52 Week Low
$0.73
$0.31
52 Week High
$1.86
$1.80

Technical Indicators

Market Signals
Indicator
EPOW
FEMY
Relative Strength Index (RSI) 33.13 51.24
Support Level $1.00 $0.79
Resistance Level $1.41 $0.91
Average True Range (ATR) 0.11 0.07
MACD -0.02 -0.02
Stochastic Oscillator 7.82 26.06

Price Performance

Historical Comparison
EPOW
FEMY

About EPOW Sunrise New Energy Co. Ltd

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: